Tern Plc to exercise warrants in Wyld Networks

Tern - Wyld Networks

Tern Plc (LON:TERN), the company focused on value creation from Internet of Things (“IoT”) technology businesses, has announced that it has committed to exercise the 320,454 TO2 Warrants in Wyld Networks AB which represents all of the TO2 Warrants that were issued to Tern pursuant to its investment as part of Wyld Networks’ Offering in conjunction with Wyld Networks’ IPO and admission to trading on the NASDAQ First North Growth Market in Stockholm on 2 July 2021.

Tern will pay SEK 2,794,359 (approximately £220,000) to exercise its TO2 Warrants to subscribe for 320,454 shares in Wyld Networks at SEK 8.72 per share, and this will be funded from Tern’s existing cash resources.

Prior to the completion of the TO2 Warrant exercises Tern held 46.5% of Wyld Networks’ issued share capital. The subscription period for the in aggregate, 2,275,000 TO2 Warrants commenced on 6 December 2022 and will end on 19 December 2022. If all of the TO2 Warrants are exercised Tern’s holding in Wyld Networks will reduce to 41.0% and a further announcement regarding Tern’s resultant holding in Wyld Networks will be made when the exercise period for the TO2 Warrants is completed.

Capitalised terms not otherwise defined herein have the same meaning as in the Company’s announcement “Proposed IPO of Wyld Networks” made on 9 June 2021.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines targets a growing data need around GLP-1 treatment journeys

Talking Medicines is using GLP-1 discontinuation conversations to show how DrugVoice can help pharmaceutical companies track changing patient needs across the treatment journey.

Device Authority adopts usage-based pricing to support KeyScaler expansion

Device Authority has moved KeyScaler to usage-based pricing, aiming to reduce licensing friction and support broader adoption of its machine identity security platform.

Talking Medicines targets growing demand for GLP-1 patient intelligence

Talking Medicines is using GLP-1 patient conversations to show how behavioural data can help pharmaceutical companies understand changing treatment expectations and engagement.

Talking Medicines builds its AI strategy around specialist life sciences intelligence

Talking Medicines is positioning specialist healthcare intelligence as the core layer that gives agentic AI useful context in life sciences.

Device Authority targets cyber resilience opportunity at TechWorks Summit 2026

Device Authority will focus on continuous IoT and OT compliance, AI and quantum risk at TechWorks Summit 2026 as it strengthens its position in connected-device security.

Talking Medicines builds a more defensible AI model for life sciences

Talking Medicines is combining proprietary healthcare intelligence, AI agents and orchestration to build a more specialised AI platform for life sciences.

Search